Search results for "zur"

showing 10 items of 321 documents

Synthesis, resolution, stereochemistry, and molecular modeling of (R)- and (S)-2-acetyl-1-(4’-chlorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinol…

2007

Abstract Recently we identified ( R , S )-2-acetyl-1-(4′-chlorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline ( 6 ) as a potent non-competitive AMPA receptor antagonist able to prevent epileptic seizures. We report here the optimized synthesis of compound 6 , its resolution by chiral preparative HPLC, and the absolute configuration of ( R )-enantiomer established by X-ray diffractometry. The biological tests of the single enantiomers revealed that higher anticonvulsant and antagonistic effects reside in ( R )-enantiomer as also suggested by molecular modeling studies.

MaleModels MolecularMolecular modelStereochemistryClinical BiochemistryPharmaceutical ScienceConvulsantsAMPA receptorCrystallography X-RayBiochemistryChemical synthesisMicrowave-assisted synthesisEnantiomeric resolutionchemistry.chemical_compoundMiceSeizuresTetrahydroisoquinolinesTetrahydroisoquinolineDrug DiscoveryAnticonvulsantAnimalsMolecular BiologyMolecular StructureTetrahydroisoquinolineOrganic ChemistryAntagonistAbsolute configurationTetrahydroisoquinoline; Microwave-assisted synthesis; Enantiomeric resolution; AnticonvulsantBiological activityStereoisomerismRatschemistryReceptors GlutamateMolecular MedicineEnantiomerExcitatory Amino Acid Antagonists
researchProduct

Inhibition of different GABA transporter systems is required to attenuate epileptiform activity in the CA3 region of the immature rat hippocampus

2014

GABA transporters (GATs) are an essential element of the GABAergic system, which regulate excitability in the central nervous system and are thus used as targets for anticonvulsive therapy. However, in the immature nervous system the functions of the GABAergic system and the expression profile of GATs are distinct from the adult situation, obscuring to predict how different GAT isoforms influence epileptiform activity. Therefore we analyzed the effects of subtype specific GAT inhibitors on repetitive epileptiform discharges using field potential and whole-cell patch-clamp recordings in the CA3 region of hippocampal slices of immature (postnatal days 4-7) rats. These experiments revealed tha…

MaleNervous systemGABA Plasma Membrane Transport Proteinsgenetic structuresTiagabineCentral nervous systemAction PotentialsHippocampusHippocampal formationPharmacologyGABA AntagonistsOrgan Culture TechniquesSeizuresmedicineAnimalsGABA transporter4-AminopyridineRats WistarbiologyChemistryNeural InhibitionTransporterCA3 Region Hippocampaleye diseasesRatsmedicine.anatomical_structureAnimals Newbornnervous systemNeurologybiology.proteinGABAergicGABA Uptake InhibitorsNeurology (clinical)medicine.drugEpilepsy Research
researchProduct

Further delineation of eye manifestations in homozygous 15q13.3 microdeletions including TRPM1: a differential diagnosis of ceroid lipofuscinosis.

2014

The 15q13.3 heterozygous microdeletion is a fairly common microdeletion syndrome with marked clinical variability and incomplete penetrance. The average size of the deletion, which comprises six genes including CHRNA7, is 1.5 Mb. CHRNA7 has been identified as the gene responsible for the neurological phenotype in this microdeletion syndrome. Only seven patients with a homozygous microdeletion that includes at least CHRNA7, and is inherited from both parents have been described in the literature. The aim of this study was to further describe the distinctive eye manifestations from the analysis in the three French patients diagnosed with the classical 1.5 Mb homozygous microdeletion. Patients…

MalePathologymedicine.medical_specialtygenetic structuresalpha7 Nicotinic Acetylcholine ReceptorEncephalopathyTRPM Cation ChannelsChromosome DisordersBiologyBlindnessEyePupilNeuronal Ceroid-LipofuscinosesNight BlindnessSeizuresIntellectual DisabilityRetinal DystrophiesGeneticsmedicineElectroretinographyMyopiaHumansEye AbnormalitiesChildGenetics (clinical)TRPM1Genetic Association StudiesCongenital stationary night blindnessGeneticsChromosomes Human Pair 15DystrophyEye Diseases HereditaryGenetic Diseases X-LinkedOptic NerveMicrodeletion syndromemedicine.diseasePenetranceChild PreschoolFemalesense organsDifferential diagnosisChromosome DeletionAmerican journal of medical genetics. Part A
researchProduct

Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience

2010

This is the first multicenter Italian experience with rufinamide as an adjunctive drug in children, adolescents and adults with Lennox-Gastaut syndrome. The patients were enrolled in a prospective, add-on, open-label treatment study from 11 Italian centers for children and adolescent epilepsy care. Forty-three patients (26 males, 17 females), aged between 4 and 34 years (mean 15.9 ± 7.3, median 15.0), were treated with rufinamide for a mean period of 12.3 months (range 3-21 months). Twenty patients were diagnosed as cryptogenic and 23 as symptomatic. Rufinamide was added to the baseline therapy at the starting dose of 10mg/kg body weight, evenly divided in two daily doses and then increased…

MalePediatricsLennox-Gastaut syndromeAtypical absence seizuresRufinamideLennox–Gastaut syndrome; Rufinamide; Orphan drug; Pediatrics; Epilepsy; Drop attacksInfantilePediatricsSpasmsEpilepsyRufinamideDrop attacks; Epilepsy; Lennox-Gastaut syndrome; Orphan drug; Pediatrics; Rufinamide; Adolescent; Adult; Anticonvulsants; Child; Child Preschool; Drug Therapy Combination; Female; Humans; Intellectual Disability; Italy; Lennox Gastaut Syndrome; Male; Spasms Infantile; Treatment Outcome; Triazoles; Valproic Acid; Young Adult; Neurology (clinical); NeurologyChildPediatricValproic AcidDrop attacksGeneral MedicineSettore MED/39 - Neuropsichiatria InfantileTreatment OutcomeItalyNeurologyAnesthesiaChild PreschoolCombinationVomitingAnticonvulsantsDrug Therapy CombinationFemalemedicine.symptomSpasms Infantilemedicine.drugAdultmedicine.medical_specialtyAdolescentClinical NeurologyIrritabilityYoung AdultDrug TherapyIntellectual DisabilitymedicineHumanspediatrics epilepsyPreschoolAdverse effectLennox–Gastaut syndrome; rufinamide; orphan drug; pediatrics epilepsy; drop attacks; refractory epilepsy.EpilepsyOrphan drugbusiness.industryLennox Gastaut SyndromeValproic Acidrefractory epilepsyTriazolesmedicine.diseaseNeurology (clinical)businessLennox–Gastaut syndromeLennox–Gastaut syndrome
researchProduct

Continuous electroencephalography in a mixed non-neurological intensive care population, an observational study.

2016

Abstract Purpose Continuous electroencephalography (cEEG) improves monitoring of the brain in unconscious patients, but implementation at ICU is difficult. The present investigation shows a way to introduce cEEG at an anesthesiological ICU and discusses the first experiences. Materials and methods The study analyzed the feasibility of cEEG, assessed the interpretable cEEG time, importance of automatic seizure detection, the incidence of seizures, the predominant background EEG activity, incidence of delirium and mortality. Results Fifty-three cEEGs of 50 patients with a median interpretable length of 24 hours [IQR 20 to 42 hours] were recorded. One patient had status epilepticus, while 5 pa…

MalePediatricsmedicine.medical_specialtyCritical CareContinuous electroencephalographyPopulationStatus epilepticusCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineOutcome predictorSeizuresIntensive careGermanyOutcome Assessment Health CaremedicineHumanseducationMonitoring Physiologiceducation.field_of_studybusiness.industryIncidence (epidemiology)030208 emergency & critical care medicineElectroencephalographyMiddle AgedIntensive Care UnitsAnesthesiaDeliriumObservational studyFemalemedicine.symptombusiness030217 neurology & neurosurgeryJournal of critical care
researchProduct

Ketogenic diet for infants with epilepsy: A literature review.

2020

Abstract The ketogenic diet (KD) is an established, nonpharmacological treatment for drug-resistant epilepsy (DRE). Actually, KD and its variants have been shown to be elective and resolute for patients with glucose transporter type 1 (GLUT1) deficiency. The aim of this review was to study the use of KD and its variants in infancy, including the neonatal age, and demonstrate the safety and efficacy of this treatment in patients with the age of 0–23 months affected by DRE already subjected to pharmacological approach attempts. A literature search was conducted using PubMed as the medical database source. We used the age limit of 0–23 months, and we considered only articles published between …

MalePediatricsmedicine.medical_specialtyDrug Resistant EpilepsyKetogenicmedicine.medical_treatmentDrug-resistant epilepsyDrug-resistant epilepsy Epilepsy Glucose transporter type 1 deficiency Infant Ketogenic diet Diet Ketogenic Disease Management Drug Resistant Epilepsy Epilepsy Female Glucose Transporter Type 1 Humans Infant. Infant Newborn. Male Seizures Treatment OutcomeNeonatal ageNewborn. MaleAge limitlaw.invention03 medical and health sciencesBehavioral NeuroscienceEpilepsy0302 clinical medicineRandomized controlled triallawSeizuresmedicineGlucose transporter type 1 deficiencyHumans030212 general & internal medicineProspective cohort studyGlucose Transporter Type 1Epilepsybusiness.industryInfant NewbornDisease ManagementInfantRetrospective cohort studyKetogenic dietInfant. InfantDrug Resistant Epilepsymedicine.diseaseDietTreatment OutcomeNeurologyFemaleNeurology (clinical)businessDiet Ketogenic030217 neurology & neurosurgeryKetogenic dietEpilepsybehavior : EB
researchProduct

NEXMIF encephalopathy: an X-linked disorder with male and female phenotypic patterns

2021

Contains fulltext : 231688.pdf (Publisher’s version ) (Closed access) PURPOSE: Pathogenic variants in the X-linked gene NEXMIF (previously KIAA2022) are associated with intellectual disability (ID), autism spectrum disorder, and epilepsy. We aimed to delineate the female and male phenotypic spectrum of NEXMIF encephalopathy. METHODS: Through an international collaboration, we analyzed the phenotypes and genotypes of 87 patients with NEXMIF encephalopathy. RESULTS: Sixty-three females and 24 males (46 new patients) with NEXMIF encephalopathy were studied, with 30 novel variants. Phenotypic features included developmental delay/ID in 86/87 (99%), seizures in 71/86 (83%) and multiple comorbidi…

MalePediatricsmedicine.medical_specialtyINTELLECTUAL DISABILITYAutism Spectrum DisorderEncephalopathyNerve Tissue ProteinsILAE COMMISSIONMOSAICISMEpilepsy/geneticsCLASSIFICATIONEpilepsyBrain Diseases/geneticsGenes X-LinkedSeizuresIntellectual disabilityGenotypemedicineHumansdevelopmental and epileptic encephalopathyMYOCLONIAAtonic seizureGenetics (clinical)Brain Diseasesddc:618Neurodevelopmental disorders Donders Center for Medical Neuroscience [Radboudumc 7]KIAA2022business.industryMUTATIONSmedicine.diseasePhenotypeAutism Spectrum Disorder/geneticsGenes X-Linked/geneticsAutism spectrum disorderintellectual disabilityNEXMIFAutismepilepsyFemaleINACTIVATIONHuman medicineSeizures/geneticsbusinessPOSITION PAPERGenetics in Medicine
researchProduct

Effects on executive functions of antiepileptic monotherapy in pediatric age.

2020

Abstract Objectives Cognitive abilities and executive functions in children and adolescents are important indicators of quality of life as well as academic and social achievements. Cognitive and executive functioning are often impaired in patients with epilepsy and can be exacerbated by seizures and antiseizure drugs. The aim of our observational retrospective study was to assess executive functioning in patients with pediatric epilepsy, currently taking a single antiseizure medication. Materials and methods Records of 172 children and adolescents aged between 6 and 18 years (mean age = 12 ± 3.4 years) with newly diagnosed epilepsy who had not yet commenced an antiepileptic treatment were i…

MalePediatricsmedicine.medical_specialtyLevetiracetamAdolescentAntiepileptic drugsOxcarbazepine03 medical and health sciencesBehavioral NeuroscienceEpilepsyExecutive Function0302 clinical medicinemedicineHumans030212 general & internal medicineOxcarbazepineChildChildrenRetrospective StudiesValproic AcidEpilepsybusiness.industrySeizure typesEpiTrack JuniorAge FactorsCarbamazepinemedicine.diseaseExecutive functionsTolerabilityCognitive functionsAntiepileptic drugs; Children; Cognitive functions; EpiTrack Junior; Executive function; TolerabilityCarbamazepineNeurologyTolerabilityQuality of LifeAnticonvulsantsFemaleCognitive functionNeurology (clinical)LevetiracetambusinessAntiepileptic drug030217 neurology & neurosurgerymedicine.drugEpilepsybehavior : EB
researchProduct

The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: A one-year observational study

2011

Abstract Purpose The long-term safety and efficacy of levetiracetam (LEV) was evaluated as add-on therapy in focal epilepsy patients ( n =491) aged at least 65 years who failed at least one monotherapy. Methods Patients ( n =491) with focal epilepsy treated with at least one antiepileptic drug in monotherapy with insufficient seizure control were included in this prospective open-label study. The recommended LEV dose range was 1000–3000mgperday. Follow-up visits were done approximately after 3, 6 and 12 months. Safety and efficacy was analysed based on all patients who received LEV (safety population, n =491) and all patients who were seen at all visits and completed the trial (per protocol…

MalePediatricsmedicine.medical_specialtyLevetiracetamEfficacyPopulationClinical NeurologyEpilepsyPharmacotherapyElderlySeizure controlmedicineHumanseducationAdverse effectAgedAged 80 and overeducation.field_of_studyEpilepsybusiness.industryGeneral Medicinemedicine.diseasePiracetamClinical trialTreatmentNeurologyAnesthesiaAnticonvulsantsDrug Therapy CombinationFemaleObservational studyEpilepsies PartialNeurology (clinical)LevetiracetamSafetybusinessmedicine.drugSeizure
researchProduct

Short-Term Neurodevelopmental Outcome in Term Neonates Treated with Phenobarbital versus Levetiracetam: A Single-Center Experience

2019

Background. Phenobarbital (PB) has been traditionally used as the first-line treatment for neonatal seizures. More recently, levetiracetam (LEV) has been increasingly used as a promising newer antiepileptic medication for treatment of seizures in neonates. Objectives. The aim of our study was to compare the effect of PB vs. LEV on short-term neurodevelopmental outcome in infants treated for neonatal seizures. Method. This randomized, one-blind prospective study was conducted on term neonates admitted to the Neonatal Intensive Care Unit of S. Bambino Hospital, University Hospital “Policlinico-Vittorio Emanuele,” Catania, Italy, from February 2016 to February 2018. Thirty term neonates with s…

MalePediatricsmedicine.medical_specialtyNeonatal intensive care unitLevetiracetamArticle Subjectneonatal seizures levetiracetam neurodevelopmental outcomemedicine.medical_treatmentneonatal seizuresNeurological examinationNeurosciences. Biological psychiatry. NeuropsychiatrySingle CenterNO03 medical and health sciences0302 clinical medicineSeizures030225 pediatricsmedicineHumansProspective StudiesProspective cohort studymedicine.diagnostic_testbusiness.industryInfant NewbornAnticonvulsants Treatment Outcome Infant Newborn Italy Levetiracetam Neurodevelopmental Disorders Phenobarbital SeizuresInfantPhenobarbital; neonatal seizures; LevetiracetamGeneral MedicineTerm neonatesNewbornNeuropsychology and Physiological PsychologyAnticonvulsantTreatment OutcomeNeurologyItalyNeurodevelopmental DisordersPhenobarbitalClinical StudyPhenobarbitalFemaleAnticonvulsantsNeurology (clinical)Levetiracetambusiness030217 neurology & neurosurgerymedicine.drugRC321-571Behavioural Neurology
researchProduct